Adalimumab (HUMIRA): a review.
Adalimumab (HUMIRA, Abbott Laboratories) is a new fully human TNF-alpha monoclonal antibody recently approved for the treatment of rheumatoid arthritis and undergoing trials for use in treating other conditions, including psoriasis and psoriatic arthritis. This article reviews its mechanisms of action, clinical trial results, and related discussion.
Scheinfeld
Noah
N
Columbia University Medical School, St.-Lukes Roosevelt Hospital Center, 1090 Amsterdam Ave., Suite 11C, New York, NY 10025, USA. NSS32@columbia.edu
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001682:Biological Availability; D006801:Humans; D007279:Injections, Subcutaneous; D011565:Psoriasis / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab